Medtech Ortho Tech constant-currency sales growth measures revenue growth in Stryker's Ortho Tech business after removing foreign-currency translation effects.
Stryker reported 10.0% constant-currency growth in Ortho Tech for the second quarter of 2026. Revenue was $717M, up from $649M.
The business was newly reorganized in 2026
Stryker combined Orthopaedic Instruments with Other Orthopaedics to create Ortho Tech and recast historical periods to the new structure.
That reorganization is essential context when comparing the business with earlier disclosures.
Ortho Tech spans equipment and orthopaedic products
Its growth should not be interpreted as a pure implant-volume or robotics metric.
Compare it with Trauma and Extremities constant-currency sales growth and Orthopaedics operating margin.
Primary source: Stryker Q2 2026 Form 10-Q.
Part of the Medtech Product Family Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- SYKOpen operating-model research →10 of 10 reviewed concepts in Medtech Product Family EconomicsOrthopaedics product growth4 of 4 bridge concepts supportedContinue through this bridge:Hips Constant-Currency GrowthKnees Constant-Currency GrowthTrauma & Extremities Constant-Currency Growth
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare Ortho Tech growth
Compare growth under Stryker's recast Ortho Tech scope without treating it as a pure implant or robotics metric.
Explore more topics in the Financial Research Encyclopedia.